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Objective: We previously demonstrated stimulation of collateral vessel formation in a rabbit model of unilateral limb 
ischaemia fter administration ofendothelial cell growth factor (ECGF). To distinguish clearly the effects of ischaemia lone 
from those of ischaemia combined with angiogenic stimulation in the same animal, a model of bilateral hindlimb ischaemia 
was used to evaluate further the angiogenic effect of ECGF. 
Design: Ischaemia was produced in both hindlimbs of 11 rabbits by femoral artery excision. ~eginning 10 days later, 
ECGF (8 mg in 3 ml of saline) was injected in one hindlimb while 3 mI of saline alone was injected in the other every other 
day for a total of five doses. 
Outcome measures: Calf systolic blood pressure was measured in both limbs on postoperative days 10, 30, and 50. On 
day 50, collateral formation was quantitated angiographically, and muscle samples were obtainedl for quantitation of 
capillary density and histologic studies. 
Results: The mean calf systolic blood pressure in the both hindlimbs was similar on day 10 (36.9 +'2,.3 versus 38.1 + 
2.9 mmHg) but was significantly higher in the ECGF-treated limb on day 30 (68.9 + 3.1 versus 45.0 ±&9 mmHg) and 
day 50 (83.0 +_ 3.0 versus 57.0 + 1.7; p < 0.0001 for both comparisons). On day 50, collateral vessei~:were significantly 
more numerous in the ECGF-treated limb (17.2 + 1.6 versus 11.0 ~_ O.& p < 0.0006), as were capillaries;(225.9 + 11.4 
versus I59.6 + 12.9 per mm2; p < 0.002). 
Conclusion: Local administration ofECGF enhanced collateral development leading to significantly improved perfusion 
in the treated as compared with the untreated limb in the same animal. Exogenous administration ofan angiogenic mitogen 
can upregulate the normal collateral response to ischaemia nd may be useful in treating severe limb ischaemia. 
Key Words: Angiogenesis; Collateral vessels; Arterial insufficiency; Growth factors. 
Introduction 
Despite normous technical advances in arterial revas- 
cularisation techniques, limb salvage and relief of 
disabling ischaemic pain remains a difficult problem 
in many patients with extensive peripheral vascular 
disease, and amputation is still the only treatment 
option for such patients. In addition, a far larger 
population of patients with stable but disabling 
claudication have no choice but to "live with" their 
symptoms because the durability of revascularisation 
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after the procedures currently employed i~;inadequate 
to warrant heir use in those not faced With limb loss 
and because no medical alternative tias been proved 
effective. 
Several new approaches to this problem have 
been reported, including omental transplantation, 1 
arteriovenous reversal, 2 and muscle pedicle flap trans- 
fer, 3 but their efficacy and practicality have not been 
established. RecentlN however, experimental work 
from several laboratories has suggested that enhanced 
collateral formation resulting from. administration of
an angiogenic growth factor might be of value in 
improving perfusion in a variety of ischaemic tis- 
sues. 4-7 For example, we demonstrated that arterial 
perfusion to an ischaemic rabbit hindlimb was dra- 
matically enhanced after administration f endothelial 
cell growth factor (ECGF). 4 In that stud34 only one 
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hindlimb in each test animal was ischaemic and the 
effect of ECGF in that limb was compared with that of 
a sham injection in a separate group of control 
animals. In order to rule out the possibility of 
interanimal variation and to control better for the 
effects of the ischaemia-rendering surgical procedure, 
we undertook the current study of the effect of ECGF 
in a rabbit model of bilateral hindlimb ischaemia. 
Materials and Methods 
Approval for the experimental protocol was obtained 
for our institutional animal care committee. The care 
of the rabbits complied with all guidelines of the 
Canadian Council for Animal Care and the "Principles 
of Laboratory Animal Care" and the "Guide for the 
Care and Use of Laboratory Animals" (NIH Publica- 
tion No. 80-23, revised 1985). 
Bilateral hindlimb ischaemia preparation 
Severe ischaemia was induced in both hindlimbs of 11 
male New Zealand White rabbits (average weight, 4 
kg) with use of a surgical procedure that has been 
shown to produce a markedly ischaemic but viable 
limb for up to 90 days. 8 Each rabbit was anaesthetised 
with intramuscular ketamine (50 mg/kg) and xylazine 
(5 mg/kg). Longitudinal incisions were made in both 
groins from the inguinal igament on each side toward 
the knee. With the aid of surgical oops, each femoral 
artery was completely dissected and its branches, 
including the profunda, lateral circumflex, and super- 
ficial epigastric arteries, were dissected as far as 
possible and the proximal popliteal and saphenous 
arteries exposed. Ischaemia was induced in both 
hindlimbs by ligation just above the inguinal igament 
of the distal external iliac arteries, the inferior epigas- 
tric arteries, all identified branches of the femoral 
arteries, and the proximal popliteal and saphenous 
arteries. The common and superficial femoral arteries 
were completely excised (Fig. 1). 
All animals received 50 ml of 0.9% sodium 
chloride during surgery. Cefazolin (15 mg/kg) was 
administered intramuscularly for 4 days beginning the 
day of surgery. Buprenorphine ata dosage of 0.04 mg/ 
kg/day was given for the first 10 days after surgery 
and longer if necrosis developed in a hindlimb. 
Administration of endothelial cell growth factor 
ECGF is a fibroblast growth factor (FGF) purified from 
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Fig. 1. Technique used to produce bilateral hindlimb ischaemia in
rabbits. Ligation sites are shown; shading indicates vessels that are 
excised. 
bovine retina and is one of the heparin-binding 
growth factors. 9 ECGF has been shown to promote 
endothelial cell proliferation in vitro (at levels of I ng/ 
ml) and to stimulate angiogenesis in vivo (at levels of 
10 fo 100 ng in the chick chorioallantoic membrane 
and cornea bioassays). 9"1° The ECGF used in this 
study (Endo Gro TM, 100mg plus 10 units of heparin/ 
per vial) was greater than 85% acidic FGF and less 
than 15% basic FGF and had a molecular weight of 
18 000 (VEC TEC Inc., Albany, N.Y., U.S.A.). 
Eight milligrams of ECGF diluted in 3 ml of saline 
and approximately 1 unit of heparin was injected 
intramuscularly into the thigh of either the right or left 
limb every other day starting on postoperative day 11 
until five doses had been administered. Each injection 
was given in three different sites (2 ml in the medial 
thigh, 0.5 ml in the lateral thigh, and 0.5 ml in the 
distal thigh near the knee). A sham injection of 3 ml of 
saline was given in the contralateral thigh in the same 
manner. The intramuscular route of administration 
was chosen to maximise the concentration of ECGF at 
the site of ischaemia nd in the area in which vessel 
growth was required. The dosage was determined 
arbitrarily, but dose-response data obtained later 
confirmed its efficacy. 1~ 
Calf blood pressure measurements 
Calf stystolic blood pressure, used as an index of 
arterial perfusion to each hindlimb, was measured in 
both limbs by a Doppler flowmeter (Model 1059, 
Parks Medical Electronics, Inc., Aloha, OR, U.S.A.) on 
postoperative days 10, 30, and 50. Both hindlimbs 
were shaved and cleaned. With the animal under 
anaesthesia, the pulse of the posterior tibial artery in 
the lower calf was detected with a Doppler probe and 
blood pressure measured in the standard fashion. The 
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measurements were done on two separate occasions 
by the same observer and the results averaged. If they 
differed by more than 10%, a third assessment was 
done and the three values averaged. 
Angiographic evaluation 
Bilateral hindlimb arteriography was performed on 
postoperative day 50 in each rabbit with use of 
standard techniques to determine the rate of recon- 
stitution of the distal arterial tree and the extent of 
vascularisation in both ischaemic limbs. With the 
animal under anaesthesia, the left common carotid 
artery was exposed through a ventral incision in the 
neck and a 4-French catheter was introduced into the 
exposed artery and advanced to about 3 cm proximal 
to the aortic bifurcation. A total of 10 ml of contrast 
agent (MD-76, diatrizoate meglumine and sodium) 
was injected at the rate of 3 ml/second, with serial 
filming of both hindlimbs. 
Collateral vessel development was quantitated by 
counting the visualised vessels in each thigh that 
intersected a line drawn perpendicularly across both 
mid-femurs on angiograms obtained 4 seconds after 
injection of contrast into the distal aorta. Vessel counts 
were done on two separate occasions by the same 
observer and the results averaged. If the two counts 
differed by more than 10%, a third count was made 
and the three values were averaged. 
ment to pH 9.2 to 9.4 with boric acid. After rinsing and 
a brief post-fixation in neutral buffered 10% formalin, 
the slides were counterstained with 0.5% eosin and 
the n subjected to alcohol dehydration, xylene clearing, 
and mounting. This technique stains capillaries black 
while leaving the rest of the muscle a light pink. 
Capillary density was measured by one of us 
(G.R.G.) according to a single-blind protocol using a 
computerised image-analysis system (Optimas, Bio- 
scan, Inc., Edmonds, WA, U.S.A.). At magnification × 
100, capillaries in 10 randomly selected fields (0.1744 
mm2/field) were counted for each muscle section and 
the results averaged. The capillary density was then 
calculated and expressed as capillaries/mm 2. 
Histologic studies 
Muscle samples were removed from the adductors in 
the mid-thighs for routine histologic studies when the 
rabbits were killed. The specimens were fixed in 10% 
buffered formalin, embedded in paraffin, and cut in 10 
~m cross-sections. Each section was then stained with 
haematoxylin and eosin for the studies. 
Statistical analysis 
Results in the two hindlimbs were compared with the 
paired Student's t test. A value of p <0.05 was 
considered significant. Values are reported as mean 
+ 1 S.E.M. 
Capillary-density measurements 
A histochemical technique that labels alkaline phos- 
phatase in capillary endothelium was used to count 
the number of capillaries in hindlimb specimens. On 
postoperative day 50, just before the rabbits were 
killed, a muscle specimen (about I cm 3) was removed 
from both the left and right adductor in the relatively 
avascular mid-thigh region (as observed on angio- 
graphy). This muscle was chosen because it is a 
principal muscle of the medial thigh and it was 
originally perfused by the ligated deep femoral artery. 
The muscle samples were frozen in methylbutane 
(precooled by dry ice). Multiple cryostat sections (10 
thick) were then cut from each sample transversely to
the directions of the fibres, fixed in acetone at 4 ° C for 
5 rains, and then air dried before staining. For each 
muscle section, staining for alkaline phosphatase with 
an indoxyl-tetrazolium ethod ~2 was done for 1 h at 
37 ° C with use of an incubation medium and adjust- 
Results 
In all 11 animals, both hindlimbs were weak when 
assessed clinically on postoperative day 10, with 
gradual recovery of function thereafter. By day 50, 
however, two rabbits had developed superficial tissue 
necrosis in the toe of the untreated limb. Calf muscle 
atrophy in the control hindlimb as compared with e 
ECGF-treated limb was readily observed both clini- 
cally (the control imbs demonstrated a smaller max- 
imum diameter) and radiographically (by assessment 
of the soft-tissue shadow of the calf muscle on 
angiographic films) in all animals. 
Calf blood pressure 
The surgical procedure consistently produced severe 
ischaemia in both hindlimbs. There was no significant 
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difference in mean calf systolic blood pressure 
between the ECGF-treated and control hindlimb on 
postoperative day 10, before the administration of 
ECGF (36.9 + 2.3 versus 38.1 + 2.9 mmHg; p = 0.48). 
However, after completion of the treatment protocol  
the blood pressure increased much more rapidly in 
the treated limb, resulting in a significant difference 
between the two limbs at subsequent evaluation 
times. Thus, on postoperative day 30, the mean 
pressure was 68.9 _+ 3.1 in the ECGF-treated limb and 
45.0 + 2.9 in the saline-treated limb (p < 0.0001). On 
day 50, the values were 83.0 + 3.0 versus 57.0 + 1.7, 
respectively (p < 0.0001). 
Revascularisation on angiography 
Satisfactory angiograms were obtained in all animals. 
There was an obvious difference between the hind 
limbs in each rabbit in that reconstitution of the distal 
vessels in the ECGF-treated hindlimb was substan- 
tially more pronounced than that in the control imb. 
Figure 2(a) is a representative film. Figure 2(b), a 
magnified view of the same animal, shows con- 
siderably more extensive collateral development in 
the left (ECGF-treated) limb than in the right (saline- 
treated) limb. Arterial vessels with a corkscrewqike 
pattern appear in the region in which the femoral 
artery was excised. These appear to be newly formed 
vessels that anastomose with the popliteal artery at 
the point at which it was ligated. 
The angiographic features hown in Fig. 2 were 
found consistently in the treated limbs, whereas 
collateral development in the control limbs was 
variable. Morphometric quantitation of the thigh 
vasculature consistently revealed a higher number of 
vessels in the ECGF-treated limb (17.2 + 1.6 versus 
11.0 + 0.8 vessels, p < 0.006). 
Capillary density 
Representative sections from both adductors in the 
mid-thigh that were assessed for capillary density are 
Fig. 2. Angiograms obtained on postoperative day 50 show earlier and more advanced distal arterial reconstitution in the ECGF-treated 
(left) hindlimb as compared with the control (right) hindlimb (a). Figure 2b is a magnified version of the same film, showing increased 
vascularity (collateral formation) in the ECGF-treated (left) thigh. 
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shown in Fig. 3. More capillaries are evident in the 
specimen from the ECGF-treated thigh than in that 
from the control imb. Quantitative analyses of capil- 
lary density consistently showed significantly more 
capillaries (p < 0.002) in muscles from the ECGF- 
treated limbs than in those from the control limbs 
(mean values, 225.9 + 11.4 vs. 159.6 + 12.9 capillar- 
ies/mm2; coefficient of variance, 16.7 for the ECGF- 
treated limbs vs. 26.8 for the saline-treated limbs). 
Histologic studies 
Histologic assessment of adductors in the mid-thigh 
revealed primarily normal skeletal muscle in both 
hindlimbs, with minimal evidence of atrophy and no 
evidence of inflammatory cell infiltration 30 days after 
administration of ECGF or saline. However, micro- 
scopical examination of the muscle samples howed 
more intramuscular terioles in the specimens from 
the ECGF-treated limbs than in those from the saline- 
treated limbs (Fig. 4). 
Discussion 
The surgical technique used in this study produced 
severe stable ischaemia in both hindlimbs of New 
Zealand White rabbits. Initial evaluation s of the 
procedure in a model of unilateral imb ischaemia 
demonstrated a profound reduction in calf systolic 
pressure ratio (left versus right) to about 0.3; this 
increased gradually to about 0.5 by day 40 and 0.6 by 
day 90. Thus, the model produced severe ischaemia 
that remained stable, with only moderate collateral 
development during the first 3 months. 
Fig. 3. Microscopical cross-section of ECGF-treated (a) and control 
(b) thigh muscles from the same rabbit as in Fig. 2. More capillaries 
(dark spots) are evident in the sample from the ECGF-treated limb. 
(Alkaline phosphatase stain; original magnification x 100). 
Fig. 4. Histological cross-section of ECGF-treated (a) and control (b) 
thigh muscles from the same animal as in Figs 2 and 3. Histologic 
studies showed normal tissue, with no evidence of inflammatory 
cell infiltration in either thigh. However, more intramuscular 
arterioles (arrows) are evident in the ECGF-treated thigh (Haematox- 
ylin and eosin stain; original magnification x 100). 
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In the current stud~ 10 days were allowed to 
elapse after the arterial inflow to the hindlimbs was 
markedly reduced to permit acute responses to the 
operative procedure to dissipate. Intramuscular ECGF 
was then injected into only one hindlimb of each 
animal. The rabbits were then monitored clinically 
and by invasive and non-invasive techniques for 50 
days to determine whether arterial flow to the treated 
limb was enhanced. Each evaluation employed 
revealed a significant improvement in perfusion to the 
limb treated with ECGF. 
Additional analysis of the calf blood pressure 
data from each time point showed that the rate of 
improvement (percentage change in mean pressure) 
between days 10 and 30 was 86.4% in the ECGF- 
treated limbs and 18.4% in the controls (a difference of 
almost 5-fold). Between days 30 and 50, however, the 
rate of change in the two limbs was similar (27% vs. 
20%). This finding suggests that the beneficial effect of 
ECGF occurred early, and it is reflective of the 
relatively short half-life of growth factors in vivo. 
Nevertheless, the augmentation i  perfusion in the 
ECGF-treated limbs was maintained for at least 50 
days, as indicated by the significantly higher pressure 
in those limbs on day 50, an outcome that can only be 
attributed to administration of the growth factor. 
These findings confirm and enhance the results of 
our previous study of the use of ECGF and provide 
additional evidence of its efficacy. In our earlier 
investigation, only one hindlimb was rendered ischae- 
mic and two separate groups of rabbits were compar- 
ed -  one that received local injections of ECGF and 
one that did not. We found higher calf systolic blood 
pressure (expressed as a leff-to-right ratio) and more 
angiographically visible vessels in the hindlimbs of 
the animals given ECGF. 4 The use of a bilateral 
ischaemic hindlimb model in the current study 
removed any unrecognised bias that may have arisen 
from comparing two different groups of rabbits. In 
addition, the extent of neovascularisation  both 
angiographic and histologic evaluation was quanti- 
tated. Furthermore, since both the control and treated 
limbs were in the same animal and identical except for 
the treatment given, all effects observed must have 
been due to the local administration of ECGF. 
Although pretreatment angiograms were not 
obtained, the consistent findings on the ankle pressure 
assessments indicate that there was no inherent 
difference between the left and right limbs before 
initiation of the treatment protocol. 
A variety of angiogenic factors have been isolated 
and studied in vitro. Of these, both basic and acidic 
heparin-binding fibroblast growth factors have been 
identified, and the two forms have been found to 
share similar gene and protein structures, in addition 
to binding to the same receptor. 13" 14 In most systems, 
basic FGF is between 10- and 100-fold more potent 
than acidic FGF, although this difference disappears in 
the presence of heparin. 14' 15 The ECGF used in this 
study (primarily acidic FGF) was bound to heparin to 
enhance its effectiveness. Although heparin itself has 
been shown to produce angiogenesis, 16 the doses 
required far exceed those used in this study (0.4 units/ 
injection). It is highly unlikel~ therefore, that the 
angiogenic effect we observed was related to the small 
amount of heparin bound to the ECGF. Indeed, studies 
of heparin-induced angiogenesis suggest that its effect 
is most likely related to its interaction with acidic 
and/or basic FGF. 17-19 
Because we were unaware of any other studies 
employing angiogenic factors for treating limb ischae- 
mia at the time we began this investigation, the route 
of administration and dose of ECGF were chosen 
somewhat arbitrarily. The intramuscular route has the 
advantages of ease of administration and the potential 
to maximise the concentration of the agent at the site 
where new vessel growth is required. We subse- 
quently conducted ose-response tudies and found 
that the doses we had employed were more effective 
than those containing 50% or 25% as much ECGF. 
Since we observed no evidence of ECGF-induced 
toxicity in any of our studies, we believe that the doses 
used were appropriate and necessary to produce a 
detectable angiogenic effect when given 
intramuscularly 
Studies of mitogens uch as ECGF have suggested 
several mechanisms by which these agents may 
induce angiogenesis. They may act directly on endo- 
thelial cells of preexisting vessels in the ischaemic 
limbs to stimulate cell locomotion and mitosis and 
thereby initiate the formation of new vessels. How- 
ever, the angiograms we obtained demonstrate that 
the vascular esponse to ischaemia is complex, with 
several components apparently involved. Successful 
revascularisation involves enlargement of native ves- 
sels from which collateral flow can occur, develop- 
ment of adequate "bridging" vessels from these native 
vessles (a phenomenon that may combine enlarge- 
ment of preexisting channels and new-vessel forma- 
tion through the area from which the native vessels 
were removed), and finally, anastomosis of these new 
channels to the native distal arterial tree. a° Analysis of 
the angiographic findings in this study suggests that 
administration of ECGF can bring about enlargement 
of preexisting vessels and stimulation of growth of 
new vessels in the ischaemic limb. In addition, tissue 
viability depends on enhanced perfusion at the micro- 
vascular level, and this study appears to show 
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evidence of significantly increased capillary and arter- 
iolar formation after intramuscular injection of 
ECGF. 
Several publications have documented the experi- 
mental use of angiogenic factors to enhance the 
healing of wounds, zl bone grafts, 2z the bronchial 
anastomosis after lung transplantation, 23 and duode- 
nal ulcers, 24 as well as to endothelialise vascular 
grafts 25 and to enhance skin-graft survival. 26 Until 
recentl)4 the ability of angiogenic agents to relieve 
organ or limb ischaemia had not been tested. 4-7"z7 
Now, however, reports of studies assessing its efficacy 
in both cardiac and hindlimb ischaemia re available. 
Banai et al. 26 were unable to demonstrate any benefit 
from delivery of an acidic FGF to ischaemic myocard- 
iurn from an epicardial sponge when regional ischae- 
mia was produced gradually by application of an 
aneroid constrictor to the left anterior descending 
coronary artery. In contrast, Yanagisawa-Miwa nd 
coworkers 7 demonstrated significantly enhanced col- 
lateralisation with intracoronary administration of 
basic FGF. The factor was injected twice into the 
circumflex coronary artery 30 minutes and 6 hours 
after the left anterior descending artery was occluded 
with thrombus. 
In studies in lower limbs, Baffour et al. 6 showed 
that daily injections of a recombinant basic FGF 
significantly improved vascular flow in a rabbit model 
of acute lower limb ischaemia. Their model, protocol, 
and experimental design, however, were different 
from those used in the current study. Our animal 
model may be more analogous to patients with 
chronic lower extremity ischaemia (such as that 
resulting from occlusion of a superficial femoral artery 
[SFA] ) than other rabbit models because the pelvic 
blood supply is left intact as a source of collaterals to 
the distal limb while the femorals (which have more 
branches in animals than does the SFA in humans) are 
removed.B, 6 The results of angiogenic stimulation in 
this study may also be more pertinent han those of 
investigations of acute ischaemia in determining the 
potential benefit of this therapy for chronic tissue or 
organ ischaemia. 5'7 This is because in our model, 
acute ischaemia is created but the animal's condition 
is allowed to stabilise for 10 days before the study is 
begun. As a result, the acute response to ischaemia 
and the inflammatory response to the surgical proce- 
dure have already occurred before therapy is begun. 
Use of the bilateral ischaemia model further controls 
for these effects, as well as any interanimal 
variability. 
The current study, therefore, provides further 
support for the use of angiogenic stimulation to 
revascularise ischaemic tissue. Such an approach may 
prove useful in, for example, salvaging ischaemic 
limbs affected by diffuse small-vessel disease not 
treatable by direct surgical technique, enhancing distal 
run-off in conjunction with a direct bypass procedure, 
or improving collateral development ~in patients not 
considered to be operative candidates. We believe that 
this studN along with our previous Work, 4 demon- 
strates unequivocally that chronic severe limb ischae- 
mia can be relieved by administration of a mitogen 
such as ECGF. If additional investigations provide 
evidence of the efficacy and safety of this approach, 
"therapeutic angiogenesis" may become the first truly 
beneficial medical alternative for the treatment of 
peripheral arterial insufficiency. 
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